Literature DB >> 9111591

Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens.

T Vejlgaard1, N Abildgaard, H Jans, J L Nielsen, L Heickendorff.   

Abstract

The main difference between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) is the presence of lytic bone destructions in the latter. About 20% of MGUS patients develop MM, and histomorphometric studies have shown disturbed bone turnover rates in some of these patients. This study was performed in order to evaluate whether serum analyses of the C-terminal telopeptide of type I collagen (ICTP), as a reflector of bone degradation, and of osteocalcin, bone-specific alkaline phosphatase (bAP) and the C-terminal propeptide of type I procollagen (PICP), as markers of bone formation, might give information on disturbances of bone metabolism in MGUS. Furthermore, serum N-terminal propeptide of procollagen III (PIIINP) might give information on disturbances in collagen III metabolism in the bone marrow. In the 35 patients examined, serum ICTP was elevated in 12 patients (34%), serum PIIINP elevated in 6 patients (17%), serum osteocalcin elevated in 11 patients (31%), serum bAP elevated in 6 patients (17%), and serum PICP elevated in 4 patients (11%). Serum ICTP correlated significantly with PIIINP (r = 0.72, p < 0.001), and with serum osteocalcin (r = 0.57, p < 0.001) and serum bAP (r = 0.51, p = 0.002). These findings indicate disturbances of bone turnover and affected collagen metabolism in some MGUS patients. Follow-up observation may reveal any prognostic value of these findings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111591     DOI: 10.1111/j.1600-0609.1997.tb00932.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  13 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 3.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 4.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

5.  Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

Authors:  Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

6.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 7.  What is the significance of monoclonal gammopathy of undetermined significance?

Authors:  Catherine Atkin; Alex Richter; Elizabeth Sapey
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

8.  Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.

Authors:  Jinxiang Fu; Panjun Wang; Xiaohui Zhang; Suguang Ju; Jie Li; Binzhou Li; Sun Yu; Jianhua Zhang; Xueguang Zhang
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

9.  Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.

Authors:  Wenting Zhang; Yexin Gu; Qiaoling Sun; David S Siegel; Peter Tolias; Zheng Yang; Woo Y Lee; Jenny Zilberberg
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

10.  BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion.

Authors:  Hany Kayed; Sandor Bekasi; Shereen Keleg; Christoph W Michalski; Thomas Giese; Helmut Friess; Jörg Kleeff
Journal:  Mol Cancer       Date:  2007-12-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.